Related Experiment Video

Updated: Jul 15, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

[Stereotactic radiotherapy for primary renal cell carcinoma: new findings from the FASTRACK trials]

Maike Trommer1, Jürgen Dunst2

  • 1Klinik für Strahlentherapie und Radioonkologie, Universitätsklinik Bonn, Bonn, Deutschland.

Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|July 14, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Jul 15, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Radiotherapy for Merkel cell carcinoma: recommendations from the DEGRO Dermatooncology Working Group.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Acute Adverse Events of Hypofractionated Whole-Breast Radiation Therapy With a Simultaneous Integrated Boost-Results From the Randomized Controlled HYPOSIB-Trial (ARO 2013-05).

International journal of radiation oncology, biology, physics·2026

Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study.

Radiation oncology (London, England)·2026

Stereotactic body radiotherapy in patients with bone oligometastases from breast cancer - results from a European multicenter cohort study.

Clinical and translational radiation oncology·2026

Outcomes of stereotactic body radiotherapy for bone oligometastases in older patients - A European multicenter cohort study.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026

Radiotherapy for indolent primary cutaneous B-cell lymphoma: an international multicenter ILROG analysis.

Blood·2026

First dosimetric evaluation of deformable dose accumulation in human individuals.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Acute toxicity and patient-reported quality of life during daily online adaptive radiotherapy versus conventional IGRT for localized prostate cancer: a prospective parallel cohort study.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Centralization of MR image-guided adaptive brachytherapy for cervical cancer in Austria: feasibility and outcomes.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Impact of PET/CT imaging on target volume delineation and radiotherapy planning in patients with locally advanced esophageal cancer.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Thirty-Two Years of Radiotherapy for T1 Anal Cancer: Patterns, Outcomes, and Side-effects at a Single Institution.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Re-irradiation in central lung cancer-a monocentric detailed analysis.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Therapeutic hybrid intelligence with neural and knowledge-based expert reasoning for SRS: an AI model for breast cancer brain metastases.

Frontiers in oncology·2026

Re-Examining the Applicability of the Linear No-Threshold (LNT) Theory in Radiation Protection for Very Low Doses: Does a Threshold Exist? The Carcinogenic Effect of Radiation and the Possibility of a Dose Threshold.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026

Comparative Physicochemical Characterization and Biological Effects of Magnetite- and Maghemite-Based Magnetic Colloidal Suspensions in A704 Renal Cancer Cells.

Pharmaceuticals (Basel, Switzerland)·2026

Drug Repurposing of Verapamil for Radiation-Induced Enteropathy: Regulation of 5-LOX, Nrf2, and Intestinal Barrier Function.

Pharmaceuticals (Basel, Switzerland)·2026

Reprogramming Photodynamic Therapy with BODIPY Photosensitizers: From Local Phototoxicity Toward Precision Photodynamic Oncology.

Molecules (Basel, Switzerland)·2026

Radiotherapy Modality and Primary Tumor Type as Determinants of Outcomes in Brain Metastases: A Retrospective Study of 734 Patients.

Medicina (Kaunas, Lithuania)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us